- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology-03-02-2012
Pharmaceutical Technology
Pharmaceutical Technology, March 2012 Issue (PDF)
March 02, 2012
Issue PDF
36
3
Solubility : Using Nanotechnology to Tackle Key Challenges in Bioavailability
Platform Technologies
March 02, 2012
Special Reports
36
3
The standardization of upstream and downstream bioprocessing is growing, but several kinks need to be ironed out.
Tackling Solubility Challenges
March 02, 2012
Special Reports
36
3
Nanosupensions are among the ways formulation scientists seek to address the problem of solubility.
Total Recall
March 02, 2012
Agent-in Place
36
3
In a world where product recalls can mean the end of a company, all batches must be perfect.
Securing the Pharma Supply Chain
March 02, 2012
Pharma Ingredients
36
3
Regulatory bodies, standard-setting organizations, and industry seek to tackle the problem of counterfeit drugs and securing the flow of pharma ingredients.
Defining Conflict of Interest
March 02, 2012
BioForum
36
3
The divide between innovation and conflict of interest in medical research is not so clear.
Genotoxic Impurities: A Q&A with Amgen's Bo Shen
March 02, 2012
Special Features
36
3
Genotoxic impurities and how to identify them and control for them have been a concern for several years in the pharmaceutical manufacturing industry. Pharmaceutical Technology spoke with Bo Shen, PhD, principal scientist at Amgen and chair of the AAPS Pharmaceutical Trace Impurities Focus Group, to gain insight on key challenges.
Report from Brazil March 2012
March 02, 2012
In the Field
36
3
Brazil's generic-drug market is growing steadily.
Inside USP: A Holistic Approach to Supply-Chain Integrity
March 02, 2012
Inside USP
36
3
US Pharmacopeia documents best supply-chain practices and seeks broad input on proposal.
Evaluating Impurities in Drugs (Part II of III)
March 02, 2012
Peer-Reviewed Research
36
3
In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.
Formulation Development Forum: Programmable, Wirelessly Controlled Microchips for Drug Delivery
March 02, 2012
Pharma Ingredients
36
3
Wirelessly controlled microchips may offer an alternative to injection-based drug delivery
Generic Drug User Fees Mark a Step in the Right Direction
March 02, 2012
Viewpoint
36
3
SOCMA's Bulk Pharmaceuticals Task Force outlines key goals and challenges for user-fee legislation.
FDA Guides the Way to Biosimilars in the US
March 02, 2012
From The Editor
36
3
Has the long-awaited guidance answered all of the industry's questions?
Communications Advances Present Manufacturer Challenges
March 02, 2012
Regulatory Watch
36
3
Social media use raises questions about applying old standards to new information technology.
FDA Encourages Whistleblowers, Just Not Its Own
March 02, 2012
PharmTech Talk
36
3
FDA's treatment of whistleblowers lacks internal consistency.
CMOs Face a Kodak Moment
March 02, 2012
Outsourcing Outlook
36
3
The evolving bio/pharmaceutical business model poses risk for CMOs.
Q&A with Chris Meissner, Meissner Filtration Products
March 02, 2012
Industry Leaders
36
3
A Q&A with Chris Meissner, president of Meissner Filtration Products, on recent industry trends.